Despite a high P/E ratio, Zhejiang Wolwo Bio-Pharmaceutical investors are holding onto their stock, risking disappointment if the P/E falls. The high share price and future earnings may not sustain the positive sentiment.
Despite equal growth projections to the market, the firm's high P/E ratio may imply investors are paying a premium, risking disappointment if P/E aligns with growth projections.
我武生物股票討論區
暫無評論